12/26/2023 0 Comments Kite pharmaMetaverse platform LAMINA1 hired Géraldine Pamphile as chief business development officer. Prior to Chamberlain Coffee, Ahern served as the director of brand marketing at Carvana.ĪBC Signature tapped former vice president of series Sydnee Rimes to SVP of series. Gen Z coffee brand Chamberlain Coffee added Liz Ahern as chief marketing officer. Howe previously served as DTx Pharma’s CFO. Lineage Cell Therapeutics, a clinical-stage biotechnology company developing allogeneic cell therapies appointed Jill Howe as chief financial officer. This milestone has been years in the making.” “Today’s FDA approval brings that hope to more patients by enabling the power of CAR-T cell therapy to be used earlier in the treatment journey. “Kite started with a very bold goal: creating the hope of survival through cell therapy,” Kite CEO Christi Shaw said in a statement. Gilead Sciences acquired Kite for $11.9 billion in 2017. Kite Pharma has focused almost exclusively on CAR-T cell therapies since it was founded in 2009. Culver City-based Appia Bio, meanwhile, emerged from stealth last spring to create off-the-shelf cell therapies that can be delivered quicker and cheaper to patients, and inked a deal with Kite Pharma last August to develop CAR-T cell treatments. In January, West Hills-based ImmPACT Bio raised $111 million to further its work of reengineering patients’ cells to boost the immune system. While most clinical CAR-T cell trials involve patients who are at an advanced stage in their cancer treatments, Yescarta’s clinical trial was filled with patients who used the drug as a second- or third-resort.ĬAR-T cell therapies have taken the oncology world by storm as a promising, potentially less invasive route for treating cancers, with many local biotech firms making moves in the space. At that point, however, their immune systems may be too weak to effectively utilize the therapeutic. Most CAR-T cell therapies are reserved as a last resort for cancer patients who have exhausted all other options. Yescarta, an intravenous CAR-T cell treatment that aims to bolster the immune system to fight cancer cells, is the first therapeutic of its kind to receive FDA approval for the early treatment of large B-cell lymphoma-a type of non-Hodgkin lymphoma-that has either relapsed or can’t be addressed with other cancer treatments like chemoimmunotherapy. The Oceanside site is just the newest addition to Kite’s group of manufacturing facilities - including others in California, the Netherlands, and in Maryland.Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a new immunotherapy drug that can be used in the early-stage treatment of certain cancers. On top of that, the pharma is investigating potential options to automate quality control testing, as every batch Kite makes is for only one patient. The operations chief noted that this was just on the manufacturing side. What we’re working on is really developing an automation platform that will take a lot of the manual steps away and automate them and also close the manufacturing process, so that we don’t have to operate aseptically, which is a huge benefit for our staff - drives a lot of efficiency. And it’s a very manual process and staff are bound quite a bit in aseptic gowning. I think right now, if you went into any lab in any university, you’re gonna see staff working under a biosafety cabinet, you know, making products, etc. McDonald added that the Gilead subsidiary is looking at automating part of the manufacturing process so that Kite can become more efficient. The vectors are the ingredient that encode the chimeric antigen receptor into a patient’s T cells. Viral vectors, according to McDonald, are a key ingredient needed for Kite to make the CAR-T cell therapies that the biotech has gotten approved to make for patients, such as Yescarta and Tecartus. ![]() The building also touts two manufacturing suites: One is fully dedicated on retroviral vectors in current commercial products, and the other is set aside for future expansion for pipeline products and potentially different types of vectors. Kite has employed 100 workers focused on viral vectors in the facility, and since the building is located on Gilead’s campus, the parent pharma will be providing logistical support, such as cafeteria staff and building security.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |